Burkitt lymphoma: click here to add to CAR-T?
In this issue of Blood, Samples et al report real-world outcomes from CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relap
In this issue of Blood, Samples et al report real-world outcomes from CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in patients with relap
Key PointsVarious types of leukemia share a hematopoietic stem and progenitor population (HSPC-like) associated with chemoresistance and poor outcome.HSPC-
Key PointsBCR-ABL drugs differentially modulate parasite and thrombin-induced activation of human brain endothelial cells.Nilotinib reduces vascular pathol
Abstract. The mechanism underlying thrombocythemia in patients with iron deficiency anemia remains unknown. Iron metabolism is highly conserved in humans a
Abstract. Background: Thrombocytosis can be a result of a reactive process such as acute blood loss, infections, iron deficiency anemia (IDA) or a clonal d
Key PointsIL-10 secretion by DLBCL cells prevents the drift of the lymphoma microenvironment toward a highly immune-suppressive state.Hallmarks of IL-10 de
Key Pointsα2-3–linked sialylation is significantly increased on CHO-rVWF compared to human pdVWF.Enhanced α2-3–linked sialylation attenuates in vivo cleara
Distinct from other chimeric antigen receptor (CAR) therapies, B-cell maturation antigen–targeted CAR T-cell therapy can cause non-immune effector cell–ass
Key PointsVEN-DEC showed not inferior response to IA-12 in young/fit patients with untreated AML.VEN-DEC had fewer serious adverse events and shorter sever
A 53-year-old woman presented with a cerebellar tumor, 2 cm in diameter. Excisional biopsy showed a fibrotic lesion (panel A, hematoxylin and eosin staining, original…
Key PointsThe surface protein CD33 is amenable to multiple modes of editing without impact on hematopoietic cell reconstitution.CD33-directed CAR T cells s